GlassScriptPhysician profile
Kevin L Ray
NPI 1194752253
$6,507.31
in general payments reported to CMS, 2019-2025
28 companies · $1,879 in 2025
The $1,879 reported for 2025 was more than what 82% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $496 · 2021: $1,917 · 2022: $961 · 2023: $299 · 2024: $259 · 2025: $1,879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,384 · Food and Beverage: $1,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,384.02 |
| Food and Beverage | $1,053.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paragon 28, INC. | $1,589.99 | 2019-2025 | Portfolio |
| Treace Medical Concepts, INC. | $1,586.11 | 2021-2024 | |
| Organogenesis INC. | $1,316.88 | 2019-2024 | Puraply |
| Triad Life Sciences INC. | $470.48 | 2022 | |
| Kerecis Limited | $293.69 | 2021-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Smith+Nephew, INC. | $207.57 | 2019-2024 | Stravix, Grafix Pl, Bone Anchors With Arthroscopic Delivery System |
| Stryker Corporation | $181.78 | 2022 | |
| Stability Biologics, LLC | $127.86 | 2025 | |
| Averitas Pharma INC. | $119.68 | 2024 | Qutenza |
| Celularity INC. | $118.00 | 2019 | |
| Horizon Therapeutics Plc | $57.02 | 2021-2023 | Krystexxa |
| Kuros Biosciences USA, INC | $50.05 | 2022-2023 | |
| Abbvie INC. | $45.25 | 2022-2023 | |
| Grt US Holding, INC. | $44.21 | 2022 | |
| Cashflow Solutions, LLC | $37.47 | 2023 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $31.00 | 2025 | Purified Cortrophin Gel |
| Kowa Pharmaceuticals America, INC. | $29.00 | 2022 | |
| Ermi LLC | $28.79 | 2020 | |
| Medtronic, INC. | $28.36 | 2023 | Intellis Adaptivestim |
| Innovation Technologies INC | $26.86 | 2023 | Irrisept |
| Crossroads Extremity Systems, LLC | $25.00 | 2020 | |
| Nabriva Therapeutics, Plc | $19.79 | 2022 | |
| Musculoskeletal Transplant Foundation INC. | $16.83 | 2019 | |
| Globus Medical, INC. | $15.58 | 2025 | Senza |
| Sanofi-Aventis U.S. LLC | $14.30 | 2019 | |
| Sebela Pharmaceuticals INC. | $13.99 | 2019 | |
| Medela LLC | $11.77 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$574,661.23 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.